"2006-01-01+01:00"^^ . "http://www.isvav.cz/projectDetail.do?rowId=NR8914"^^ . . "14"^^ . . "14"^^ . . . " VEGF" . . "The clinical significance of angiogenic markers in patients with renal cell carcinoma"@en . "The project cotributed to understanding of the role of angiogenic factors during development of renal carcinoma."@en . "2011-04-27+02:00"^^ . . "0"^^ . " bFGF" . . "2009-12-18+01:00"^^ . "1"^^ . "NR8914" . . . . "2009-12-31+01:00"^^ . . "renal cell carcinoma; angiogenesis; endoglin; VEGF; bFGF; TGF"@en . "0"^^ . . . "To verify the soluble and membrane associated angiogenic factors reflected the growth activity of renal cell carcinoma and set up there prognostic value. To pick out some parameters (VEGF, bFGF, TGF, CD105) to determine the risk of progression of RCC in time of diagnosis. To use the flow cytometry for detection of CD105 expression on membranes of tumor and endothelial vessel cells. To verify the diagnostic importance of repeated detection of angiogenic factors during the relaps of disease."@en . "Sledov\u00E1n\u00ED marker\u016F angiogeneze u nemocn\u00FDch s ren\u00E1ln\u00EDm karcinomem a jejich klinick\u00E9 vyu\u017Eit\u00ED" . . . " endoglin" . "Stanovit solubiln\u00ED a na bu\u0148ky v\u00E1zan\u00E9 angiogenn\u00ED faktory odr\u00E1\u017Eej\u00EDc\u00ED r\u016Fstovou aktivitu karcinomu ledviny a stanovit prognostick\u00FD v\u00FDznam. Pomoc\u00ED vybran\u00FDch parametr\u016F (VEGF, bFGF, TGF a CD105) stanovit riziko progrese karcinomu ledviny v \u010Dase stanoven\u00ED diagn\u00F3zy. Pomoc\u00ED pr\u016Ftokov\u00E9 cytometrie stanovit expresi CD105 (endoglin) na n\u00E1dorov\u00FDch bu\u0148k\u00E1ch a bu\u0148k\u00E1ch c\u00E9vn\u00EDch epiteli\u00ED. Zjistit, zda opakovan\u00E1 stanoven\u00ED hladin angiogenn\u00EDch faktor\u016F mohou odhalit progresi karcinomu ledviny." . . "renal cell carcinoma" . . " angiogenesis" . "\u0158e\u0161en\u00ED projektu p\u0159isp\u011Blo k pochopen\u00ED \u00FAlohy angiogenn\u00EDch faktor\u016F b\u011Bhem v\u00FDvoje ren\u00E1ln\u00EDho karcinomu."@cs . .